Crucell and DSM Biologics have chosen Invitrogen to enter its partnership for the PER.C6 licensing business Vendor Network for monoclonal antibodies and recombinant proteins. Through its PD-Direct services, Invitrogen has experience with the PER.C6 technology and will offer PER.C6 licensees the benefit of expertise developed as a leader in clone generation services. Invitrogen will also continue to develop and optimize clone generation solutions specifically tailored to the PER.C6 human cel...